This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
BACKGROUND: High-flow nasal cannula (HFNC) use is increasing in pediatric patients. Objective measures that predict HFNC outcomes are lacking. The respiratory rate-oxygenation (ROX) and ROX heart rate (ROX-HR) indices are validated to predict HFNC therapy failure in adults. This study examined the performance of both indices in predicting HFNC therapy failure in children admitted to the pediatric ICU (PICU).
METHODS: This retrospective, longitudinal, observational cohort study was completed in a 24-bed PICU in a quaternary care children’s hospital. All subjects ≤ 24 months of age initiated on HFNC in the PICU from January 1, 2018–August 31, 2020, were included. The ROX and ROX-HR indices were collected at standardized time points during HFNC therapy. Performance in predicting HFNC failure was evaluated using area under the receiver operating characteristic curve (AUROC) and Kaplan-Meier survival analysis. Failure was defined as escalation of respiratory support to either noninvasive ventilation or endotracheal intubation.
RESULTS: Among 446 subject encounters, 111 (24.9%) failed HFNC therapy. HFNC failure was associated with lower ROX and ROX-HR indices at termination compared to HFNC liberation (P < .001). A ROX-HR index < 3 was significantly associated with a higher risk of HFNC failure at 1 (AUROC 0.76, P = .01) and 6 (AUROC 0.81, P = .02) h.
CONCLUSIONS: ROX-HR may be a useful tool for early identification of patients ≤ 24 months at risk for HFNC failure and allow for earlier intervention. Larger prospective studies are necessary to validate the utility of the ROX-HR index in pediatric patients.
- pediatrics
- critical care
- bronchiolitis
- noninvasive ventilation
- respiratory insufficiency
- high-flow nasal cannula
Footnotes
- Correspondence: Lece Webb MD, Department of Pediatrics, Division of Critical Care Medicine, University of Alabama at Birmingham, 1600 5th Avenue South, CPPI Suite 102, Birmingham AL, 35294. E-mail: lvwebb{at}uabmc.edu
See the Related Editorial on Page 1493
The authors have disclosed no conflicts of interest.
- Copyright © 2022 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
